The Beauty Standard with Dr. Roy Kim

Letybo: A New Botox Alternative

• Dr. Roy Kim

Share episode

Unlock the secrets to a more youthful appearance with Dr. Roy Kim as we explore Letybo, the revolutionary Botox competitor making headlines in the aesthetics world. What makes Letybo a potential game-changer? Our latest episode dives into the unique formulation of Letibitolymtoxin A, the newest offering from South Korean innovator Hugel, in partnership with Benev. Learn how Letybo might offer faster onset results and longer-lasting impacts, providing new hope for those who haven't found success with traditional Botox. Join us as we discuss Hugel's impressive journey to securing FDA approval, marking a significant milestone as the first Korean company to achieve this feat across the US, Europe, and China.

We'll also uncover how Lettybo could transform the cosmetic scene with its strategic launch anticipated in 2025. With Benev's expertise in cosmeceuticals, particularly in the realm of exosomes, this partnership could redefine the way we approach facial aesthetics. Curious about the buzz around potential pricing? Hear our insights on how Letybo, potentially priced lower, could capture market share and attract new clients seeking smoother skin. With Letybo poised to reshape the landscape of aesthetic treatments, this episode promises a comprehensive look at what might be the future of facial rejuvenation. Don't miss out on this in-depth discussion; your journey to smoother skin starts here.

Thank you for tuning in to this week's episode of "The Beauty Standard" with Dr. Roy Kim! If you enjoyed this episode, please make sure to subscribe, rate, and leave us a review on your favorite podcast platform. Your support helps us continue to bring you the latest insights in aesthetic medicine and beauty trends.

Connect with us on social media on Instagram - @drroykim - or X - @drroykim- for more exclusive content, behind-the-scenes looks, and expert advice from Dr. Kim. Feel free to submit your questions or suggestions for future episodes – we'd love to hear from you!

Join us next week as we explore another fascinating topic in the world of beauty, and remember: your body, your choice, your standard!

Speaker 1:

Welcome to the Beauty Standard with Dr Roy Kim.

Speaker 2:

Hey, everyone ready for another deep dive? Today we're taking a closer look at Lettybo, the new Botox competitor. That's got everyone talking.

Speaker 1:

Definitely exciting, especially since it comes from Hugo, a South Korean company that's a big deal in aesthetics overseas.

Speaker 2:

Right and they've teamed up with Benev here in the US to handle the launch.

Speaker 1:

Like a dream team, each bringing their A game.

Speaker 2:

Okay, so we've got this power duo behind Letibo. But for those who haven't heard all the buzz, what exactly is Letibo?

Speaker 1:

Letibo or Letibitolymtoxin A well, a BG is a neurotoxin just like Botox.

Speaker 2:

Okay.

Speaker 1:

It's made to smooth out those frown lines between your eyebrows. You know this little vertical line.

Speaker 2:

Oh, the dreaded 11s. I know them well. Exactly so. Lidabo targets those same muscles that Botox does.

Speaker 1:

Mm-hmm.

Speaker 2:

But what makes it stand out? Is it just like another version of the same thing?

Speaker 1:

It's similar, yeah, but with some potentially key differences.

Speaker 2:

Okay.

Speaker 1:

Think of the muscles between your brows like tiny ropes. You know that pull your skin together and create those lines I see yeah ledebo, like botox, blocks the signals from your nerves to those muscles okay prevents them from contracting and allows your skin to smooth out same basic mechanism, but I've heard whispers that liddybo might have some extra perks.

Speaker 2:

Yeah, what's the deal with that?

Speaker 1:

exactly one benefit is that lennybo might work faster than Botox.

Speaker 2:

Oh.

Speaker 1:

So you get the injection and instead of waiting like five to seven days to see results, Right. You might see a difference in just a few days.

Speaker 2:

Wow, now that would be a game changer, especially if you have a big event coming up. Who wants to wait a whole week?

Speaker 1:

Right, and on top of that, there's a chance Lidibo could last longer than Botox, really. Yeah, it's still based on what people are saying, but some are reporting that the effects are sticking around longer, so you might not need to go back for touch-ups as often.

Speaker 2:

Okay, fewer injections, over injections and dear eyes, longer-lasting results. That's music to my ears, but you did mention this is anecdotal, right.

Speaker 1:

What does the hard evidence say? So clinical trials have proven Lenny Bo is safe and effective for frown lines. But we're still waiting on the long-term data to confirm those quicker results and longer duration Makes sense. But you know, the early buzz is exciting.

Speaker 2:

Excitement is right and it's not like this is some brand new untested product. I've even heard it's a bestseller in South Korea, where it's known as Botulax seller in South Korea, where it's known as Botulax.

Speaker 1:

It's true, linadipo has been a top performer in South Korea for years, and Hugol didn't just breeze through the FDA approval process here. Oh, it took three tries to get the green light.

Speaker 2:

Right.

Speaker 1:

Which really says something about their dedication.

Speaker 2:

Three attempts Wow, they really persevered. That tells me they're serious about making their mark here.

Speaker 1:

They are, and this FDA approval is a huge win. It makes Hugel the first Korean company to have its neurotoxin approved in the US, Europe and China.

Speaker 2:

Wow, that's impressive. Okay, so we've got a high quality product with a proven track record, but what about Benev? What are they bringing to the table?

Speaker 1:

Benev is a well-established player in the US aesthetics market. They have expertise in cosmeceuticals, especially exosomes.

Speaker 2:

Exosomes.

Speaker 1:

Yeah, those tiny particles that show real promise in skin rejuvenation.

Speaker 2:

So they already have a foothold in the market and a deep understanding of how to reach aesthetics professionals and consumers. Right, that's huge it is. But I'm curious how might Benev leverage their knowledge of exosomes to benefit Letty Bow's launch? Could there be a connection there?

Speaker 1:

That's a great question. Knowing how to market cutting edge skincare definitely gives Benev an advantage.

Speaker 2:

Yeah.

Speaker 1:

They're already familiar with introducing innovative products to a discerning audience. Makes sense, and who knows, maybe their expertise in exosomes could even open doors for future research with Hugel.

Speaker 2:

Now that you mention it, it makes me wonder if their knowledge of advanced skin care could inform how they educate practitioners about Ledibo.

Speaker 1:

Absolutely. Banev's understanding of those intricate skin mechanisms could give them a unique edge.

Speaker 2:

Okay, so we have this dynamic duo, a potentially game-changing product and a whole lot of buzz, but the million-dollar question is when will Ledibo actually be available here in the US?

Speaker 1:

Everyone wants to know. Sadly, no official launch date yet.

Speaker 2:

Yeah.

Speaker 1:

But the rumor mill says 2025.

Speaker 2:

2025,? Huh, that's not too far off. But while we're waiting, I think it's important to dig deeper into what makes Letty Bow different from Botox. Everyone knows Botox it's been the go-to for years, right? So what could make someone choose Letty Bow over the tried and true?

Speaker 1:

That's where the faster onset and longer duration come in.

Speaker 2:

Okay, yeah.

Speaker 1:

Let's imagine two scenarios one with Botox and one with Letty Bow. Okay, I'm all ears. Let's say you have a wedding coming up in two weeks. Okay, With Botox you'd need to get your injections at least a week in advance maybe more, to ensure those frown lines are smoothed out in time.

Speaker 2:

Yeah.

Speaker 1:

But with Letibo, if those faster onset claims hold true, you might be able to get those injections just a few days before the big day, giving you more flexibility and less worry.

Speaker 2:

Oh, I can definitely see the appeal there, especially for those last minute events or if you just tend to procrastinate.

Speaker 1:

Exactly, and then there's the potential for longer lasting effects. Instead of going back for touch-ups every three to four months with Botox, imagine only needing Letty Bo injections twice a year. Wow, that means fewer appointments, less discomfort and potentially lower costs in the long run.

Speaker 2:

Okay, that definitely makes Lidibo sound tempting. Yeah, but even with these potential perks, I have to ask are there any downsides or things people should be aware of before jumping on the Lidibo bandwagon?

Speaker 1:

That's a crucial point. While Lidibo has shown a strong safety profile in clinical trials comparable to Botox, it's important to remember that no medical treatment is completely risk-free.

Speaker 2:

Of course.

Speaker 1:

Potential side effects like temporary bruising, swelling or headaches are possible.

Speaker 2:

Right, and it's always essential to have a thorough consultation with a qualified practitioner to discuss your individual needs, any potential risks and your expected outcomes. Informed consent is key, no matter what treatment you're considering.

Speaker 1:

Absolutely, and it's worth noting that we're still gathering long-term data on Lidibo. As with any new product, ongoing monitoring and research will be crucial to fully understand its benefits and any long-term effects.

Speaker 2:

That's a good reminder for everyone Stay informed, ask questions and prioritize your health and well-being. Okay, so we've covered the basics, but what about those folks who haven't had success with Botox? Is there any reason to believe Letibo might work for them where Botox hasn't?

Speaker 1:

That's a really interesting question and one that deserves its own deep dive, yeah, so after a quick break, we'll explore why Letibo might offer hope for those who've been disappointed by Botox in the past.

Speaker 2:

Ooh, can't wait.

Speaker 1:

Stay tuned.

Speaker 2:

We'll be right back with more on Letibo, the Botox competitor. That's got everyone talking. That's right, we're back, and before the break we were talking about how Letibo might be a game changer for those who haven't had success with Botox.

Speaker 1:

It's definitely intriguing. Yeah, you see, even though Letibo and Botox are both botulinum toxin type A, there are subtle differences in their formulations. Okay, think of it like baking a cake you can have the same basic ingredients, but slight variations in the recipe can lead to distinct results.

Speaker 2:

So, even though they both target those same wrinkle-causing muscles, the way they're formulated could influence how they interact with the body.

Speaker 1:

Exactly. These variations can affect factors like how the neurotoxin spreads within the muscle, how quickly it binds to nerve receptors and even how long it stays active. Oh wow, it's like each neurotoxin has its own personality and style.

Speaker 2:

So it's possible that Letty Bow's unique personality might like click with some people's bodies in a way that Botox doesn't.

Speaker 1:

Exactly. It's still early and we need more research to understand why some people don't respond to Botox, but one theory is that their bodies might develop antibodies that neutralize the toxin, making it ineffective. Now, lidibo's unique formula could bypass those antibodies, allowing it to work where Botox has failed.

Speaker 2:

That's fascinating. So for those who felt like they were stuck with those stubborn frown lines, what an Ebo could offer some hope.

Speaker 1:

It's certainly worth exploring. Of course, anyone considering Leggy Bo, especially if they haven't responded to Botox, should consult with a qualified practitioner.

Speaker 2:

Right, of course.

Speaker 1:

They can assess your individual situation and determine if Lady Bo is the right choice.

Speaker 2:

That's such an important reminder. Every treatment is a personal decision, and a good practitioner will always prioritize your safety and well-being. Okay, we've talked a lot about the potential benefits, but let's shift gears for a moment. You mentioned that it took Hugel three attempts to secure FDA approval for Lady Bow.

Speaker 1:

Yeah.

Speaker 2:

What were?

Speaker 1:

some of the hurdles they had to overcome. Well, the FDA approval process for any drug is incredibly rigorous, especially a neurotoxin.

Speaker 2:

Yeah.

Speaker 1:

It involves multiple phases of clinical trials, and each phase is designed to evaluate the safety and efficacy of the treatment. Okay Hugel first submitted Ladybo for FDA approval back in 2021, but they received what's called a complete response letter.

Speaker 2:

A complete response letter. What does that even mean?

Speaker 1:

Basically it means the FDA had some concerns or questions that needed to be addressed before they could grant approval.

Speaker 2:

Okay, these concerns could range from the design of the clinical trials to the manufacturing process or even the data analysis.

Speaker 1:

So it's not a flat-out rejection, but more like a request for more information.

Speaker 2:

Precisely yeah, hugel took the FDA's feedback seriously, conducted additional studies and resubmitted their application in 2022. Okay, but they received another complete response letter, this time related to manufacturing facility inspections.

Speaker 1:

Oh wow, that must have been frustrating.

Speaker 2:

It was a setback, for sure, but Hugel was committed to bringing Luddebo to the US. They addressed the FDA's concerns, made the necessary adjustments to their manufacturing processes and resubmitted their application for a third time in 2023.

Speaker 1:

And the third time was the charm.

Speaker 2:

It was. They finally received that FDA approval in March 2024.

Speaker 1:

Talk about persistence.

Speaker 2:

It really shows their dedication and belief in Ledibo's potential.

Speaker 1:

Yeah.

Speaker 2:

They could have easily given up after those first two setbacks, but they kept pushing forward.

Speaker 1:

Right.

Speaker 2:

Demonstrating their commitment to meeting the highest regulatory standards. That really speaks volumes about their integrity and commitment to bringing a safe and effective product to the market. But I'm curious during this whole approval process, were there any major concerns about LaboBot's safety or effectiveness?

Speaker 1:

Throughout the clinical trials and the FDA's review, labobot consistently demonstrated a strong safety profile comparable to Botox. The most common side effects reported were mild and temporary, like bruising, swelling or headache.

Speaker 2:

So nothing out of the ordinary for this type of treatment.

Speaker 1:

Exactly. The FDA's approval is a strong endorsement of Lady Bo's safety and effectiveness for treating frown lines. And now, with that approval secured and their partnership with Benev in place, Hugel is poised to make a big impact.

Speaker 2:

I'm starting to see why everyone's so excited about Lidibo. It's got a lot going for it Potential advantages like faster onset and longer duration, a solid track record overseas, a rigorous FDA approval process and a strategic partnership with a company that knows the US market inside and out.

Speaker 1:

It's a powerful combination, but let's not forget the potential benefits for patients. If Lidibo lives up to its promise, it could offer a more convenient, effective and potentially even more affordable way to address those frown lines.

Speaker 2:

More options, better outcomes and potentially less time and money spent on treatments. That's a win-win for everyone.

Speaker 1:

Right.

Speaker 2:

But I know our listeners are probably wondering how Lidibos pricing will compare to Botox. Will it be more expensive, less expensive or somewhere in between?

Speaker 1:

That's the million dollar question. Pricing will play a huge role in Lidibos success.

Speaker 2:

Exactly. If it's significantly more expensive, people might be hesitant to switch, even with the benefits. But if it's priced competitively, it could really shake things up.

Speaker 1:

Danielle Pletka, you're absolutely right. Hugel and Benev haven't released any official pricing info yet, but there's a lot of speculation. Some experts believe they might go for a slightly lower price point to attract new customers and gain market share. O'reilly.

Speaker 2:

That would be a bold move considering Botox's dominance, but it could be a brilliant strategy to disrupt the market and make Latibo more accessible.

Speaker 1:

Exactly. On the other hand, they might choose to position Latibo as a premium product.

Speaker 2:

Okay.

Speaker 1:

Highlighting its potential advantages and appealing to those who are willing to pay a bit more for potentially faster and longer-lasting results.

Speaker 2:

That's a smart strategy too. It could create a perception of exclusivity.

Speaker 1:

Right.

Speaker 2:

But ultimately the pricing decision will come down to a lot of factors.

Speaker 1:

Definitely.

Speaker 2:

Production costs, profit margin, their target market and the competitive landscape.

Speaker 1:

It's a delicate balancing act. They'll need to find that sweet spot that keeps them profitable while also appealing to consumers and staying ahead of the competition.

Speaker 2:

It makes me wonder what kind of impact Lidty Bow could have on the overall aesthetics market. Could it really challenge Botox?

Speaker 1:

That's the question everyone's asking, and while it's too early to predict the future, letty Bow's arrival is already generating a lot of excitement.

Speaker 2:

I bet, but let's dig into those potential market impacts after a quick break Sounds good. We'll be back with more on Letty Bo and its potential to reshape the world of aesthetics. We're back and ready to unpack this whole Letty Bo thing and the impact it could have.

Speaker 1:

Yeah, it's pretty wild to think how one product could shift things so much. It really is. You know, botox has been king for so long it's practically a generic term.

Speaker 2:

Right, you see Botox and everyone just gets it. But could Letty Bo change that? Become the new go-to.

Speaker 1:

Definitely possible. Think about what it brings Faster onset, longer duration.

Speaker 2:

Right.

Speaker 1:

That's huge for both patients and D practitioners.

Speaker 2:

Yeah, who wouldn't want results in days instead of a week, exactly, and fewer trips to the clinic, that's convenience and D cost savings Exactly. And wouldn't want results in days instead of a week, exactly, and fewer trips to the clinic, that's convenience and cost savings Exactly.

Speaker 1:

And don't forget about Letty Bo, possibly working for people who haven't had success with Botox. Oh right, that opens up a whole new market.

Speaker 2:

It does. It's like Letty Bo could expand the entire market, not just take a piece of it.

Speaker 1:

Exactly, and Hugo partnering with Benev.

Speaker 2:

Genius yeah. Benev already has those relationships with practitioners Right and they get the US market. They're not starting from scratch that's for sure.

Speaker 1:

Nope, they're coming in strong Right and they seem to understand. It's not just about the product, it's about the whole experience. They're going to invest in marketing and education.

Speaker 2:

Makes sense.

Speaker 1:

Make sure everyone understands what Letty Bells can do.

Speaker 2:

Speaking of marketing. Everyone understands what Letty Bells can do.

Speaker 1:

Speaking of marketing.

Speaker 2:

I'm curious how they'll position Letty Bell. Will it be premium, even pricier than Botox, or will they aim for a wider audience?

Speaker 1:

That's the big question, and it'll have a huge impact. A premium strategy could create the sense of exclusivity, appealing to those who want the best.

Speaker 2:

The luxury car of wrinkle relaxers.

Speaker 1:

Exactly, but a more competitive price could make it accessible to a much larger market, potentially drive down the cost of treatments overall.

Speaker 2:

That could be huge EE for the industry. Imagine if more competition led to more affordable treatments.

Speaker 1:

It's possible and regardless of pricing, Letty Bow entering the market is going to spark innovation.

Speaker 2:

Right. Competition usually pushes everyone to be better.

Speaker 1:

Exactly. Other companies might step up their game to stay competitive. Yeah.

Speaker 2:

Improve their formulas, offer new solutions.

Speaker 1:

And ultimately the patients are the ones who benefit More options, better results, maybe even lower prices. It's an exciting time.

Speaker 2:

It really is. So, as we wrap up our deep dive into Ladybo, what's the one thing you want our listeners to remember?

Speaker 1:

I think the most important message is this Ladybo shows that innovation is happening. There might be even better solutions coming for those looking for a more youthful appearance.

Speaker 2:

That's a great point. Ladybo is more than just a product. It's a sign that this field is constantly evolving.

Speaker 1:

Exactly and for anyone thinking about these treatments. Do your research, talk to a qualified practitioner and make informed decisions that are right for you.

Speaker 2:

Well said. So to everyone listening, stay curious, stay informed and keep an eye out for Ladybow.

Speaker 1:

It might just be the change we've been waiting for.

Speaker 2:

It might be Thanks for joining us on the Deep Jive.

Speaker 1:

Thanks for having me. Thank you for listening to the Beauty Standard with Dr Roy Kim. Make sure to follow for future topics and episodes.